Sanofi (NASDAQ:SNY) is one of the Most Undervalued International Stocks According to Analysts. On August 14, Sanofi (NASDAQ:SNY) announced receiving an orphan designation for its Rilzabrutinib by the ...

Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges ...

The Asia–Pacific region has a high global burden of cardiovascular disease.1 The region, home to more than 60% of the world's population, spans the vast and diverse geographies from Oceania through ...

On August 22, Ryan Detrick, Carson Group chief market strategist, joined CNBC for an interview to discuss the bull market run ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies ...

It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...

Sanofi (ENXTPA:SAN) has made a move that is bound to get investors talking, as shares edged up just over 5% in the past week. While there is no headline-making event at play, this uptick arrives after ...

Read about Sanofi India Ltd company details like share price, management, news and more at IIFL Capital.

Patients with chronic rhinosinusitis with nasal polyps show high treatment persistence with dupilumab, with a substantial proportion restarting therapy after discontinuation.